EnteroMedics, Inc. (ETRM) – Buzz Stock of the Day

Shares of medical device maker, EnteroMedics, Inc. (Nasdaq: ETRM) soared 75 percent from Monday’s closing price, in morning trading on Tuesday after the company announced positive data from an ongoing feasibility study of the Maestro System in obese patients with Type-2 diabetes mellitus. The study was designed to evaluate the safety and efficacy of the Company’s next-generation Maestro RC System, which treats obesity.

James Toouli, M.D., professor of surgery at Flinders University in Adelaide, Australia, and one of the study’s investigators said the results from the study showed “significant, sustained improvements in glycemic control and blood pressure as well as clinically meaningful weight loss, without a compromise in patient safety.”

[–quote–]

Data from the Empower study, in which over 400 patients have used the Maestro System device, showed significant weight loss and control of obesity related co-morbidities.

EnteroMedics’ device, which is implanted laparoscopically, blocks the vagus nerves periodically using high-frequency, low-energy electrical impulses.

“Across a number of studies, we have observed clinically significant weight loss and control of obesity related co-morbidities as well as a safety profile that distinguishes this system from all other bariatric surgical procedures. We are particularly encouraged by the strong, positive feedback from the metabolic and bariatric surgery community,” said EnteroMedics’ President and CEO Mark B. Knudson, Ph.D in a statement.

Tags: Biotech Stocks, etrm, nasdaq, obesity, Penny Stocks

This entry was posted on Tuesday, June 22nd, 2010 at 3:55 pm by admin and is filed under Health Care Stocks, Penny Stocks, Technology Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.